Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06733038
Title FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients. (AtezoTRIBE2)
Acronym AtezoTRIBE2
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Gruppo Oncologico del Nord-Ovest
Indications
Therapies
Age Groups: adult | senior
Covered Countries ITA

Additional content available in CKB BOOST